Geneva (July 2, 2025) – SGS, the world’s leading testing, inspection and certification company, is pleased to announce a complimentary webinar titled ‘Biocompatibility Testing – In Vitro and Animal Alternative Tools for ISO 10993 Evaluations’, taking place on July 15, 2025.
With regulatory authorities placing growing emphasis on biological safety, medical device manufacturers must now provide clear, risk-based biocompatibility evidence aligned with ISO 10993 requirements, within the broader context of ISO 14971 risk management. Foundational tests for cytotoxicity, sensitization and irritation remain critical components of any compliant biological evaluation strategy.
In this live webinar, SGS experts Bruce Yang, Toxicologist, and Sebastien Vogel, Customer Service Group Leader, will share practical insights and regulatory strategies for designing and implementing biocompatibility plans that meet current regulatory expectations. Topics will include risk assessment design, test selection, sample preparation, extraction protocols and advances in animal-alternative testing.
The session will focus on in vitro testing capabilities under ISO 10993-5, -12 and -23, and is ideal for professionals in medical device R&D, manufacturing, quality or regulatory affairs, especially those involved in biocompatibility testing or managing products with biological safety considerations.
Following the presentation, attendees will have the opportunity to ask the experts specific questions related to their products and testing strategies.
Interested parties can learn more by registering for the webinar.
To find out more on the medical industry and test measurement , take a look at Irish Manufacturing’s News Page
